Biohaven Pharmaceutical Holding Company Ltd - Rimegepant Migraine Prevention Topline Data Webcast
Conference Call Biohaven Pharmaceutical Holding Company Ltd
Biohaven Pharmaceutical Holding Company Ltd Conference call will be held on Mar 30, 2020. During the earnings conference call's session Biohaven Pharmaceutical Holding Company Ltd will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Biohaven Pharmaceutical Holding Company Ltd for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We are a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Our product candidates are small molecules based on two distinct mechanistic platforms--calcitonin gene-related peptide ("CGRP"), receptor antagonists and glutamate modulators--which we believe have the potential to significantly alter existing treatment approaches across a diverse set of neurologic indications with high unmet need in both large markets and orphan indications. The most advanced product candidate from our CGRP receptor antagonist platform is rimegepant, an orally available, potent and selective small molecule human CGRP receptor antagonist that we are developing for the acute treatment of migraine. We expect to receive the topline results of our two Phase 3 clinical trials in the first quarter of 2018.Read more Conference Call